GRDN on NYSE
Guardian Pharmacy Services, Inc.
American Retail-Drug Stores and Proprietary Stores company1
In its 2026 annual report the company says: “We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes.”5 It is headquartered in Atlanta, Georgia.1 Its shares trade on NYSE under the symbol GRDN.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with 111, Inc., PetMed Express or Ridgetech Inc., or pick any stock.
- TickerGRDN on NYSE1
- IndustryRetail-Drug Stores and Proprietary Stores1
- HeadquartersAtlanta, Georgia1
- Incorporated inGA3
- Business address300 Galleria Parkway Se, Suite 800, Atlanta, Ga 303393
- Filer categoryAccelerated filer3
See how the biggest companies compare on our leaderboards
We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. We emphasize high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as assisted living facilities (“ALFs”), and behavioral health facilities and group homes (collectively “BHFs”). More than two-thirds of our annual revenue for each of the past three years has been generated from residents of ALFs and BHFs, which are our target markets, while the remainder has been generated primarily from residents of skilled nursing facilities (“SNFs”). Additionally, our robust suite of capabilities enables…5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
20.2%Gross margin2
5.0%Operating margin2
3.4%Net margin2
17.9%Revenue growth, 20252
22.6%Return on equity2
0.00×Debt to equity2
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue80¢$1.2B
- Selling, general and admin15¢$220.0M
- Income tax2¢$24.5M
- Profit3¢$49.2M
Out of $1.4B in revenue.2
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢$100.3M
Out of $100.3M of cash from operations.2
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $1.4B | $1.2B |
| Cost of goods sold | $1.2B | $984.0M |
| Gross profit | $292.7M | $244.4M |
| Selling, general, and administrative expenses | $220.0M | $307.3M |
| Operating income (loss) | $72.7M | -$62.9M |
| Interest expense | $665.0K | $3.3M |
| Other expense (income), net | -$1.4M | $279.0K |
| Total other expenses (income) | -$722.0K | $3.6M |
| Income (loss) before income taxes | $73.4M | -$66.5M |
| Provision for income taxes | $24.5M | $4.6M |
| Net income (loss) | $49.0M | -$71.0M |
| Less net income attributable to Guardian Pharmacy, LLC prior to the Corporate Reorganization | $0 | $22.8M |
| Less net income (loss) attributable to non-controlling interests | -$261.0K | $16.3M |
| Net income (loss) attributable to Guardian Pharmacy Services, Inc. | $49.2M | -$110.0M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $65.6M | $4.7M | |
| Accounts receivable, net | $101.6M | $97.2M | |
| Inventories | $43.4M | $40.5M | |
| Other current assets | $11.0M | $9.6M | |
| Total current assets | $221.6M | $152.0M | |
| Property and equipment, net | $55.5M | $49.9M | |
| Intangible assets, net | $18.5M | $14.9M | |
| Goodwill | $79.7M | $69.3M | |
| Operating lease right-of-use assets | $34.6M | $29.1M | |
| Deferred tax assets | $2.2M | $5.3M | |
| Other assets | $436.0K | $383.0K | |
| Total assets | $412.7M | $320.8M | |
| Accounts payable | $116.2M | $102.4M | |
| Accrued compensation | $15.0M | $14.4M | |
| Operating leases, current portion | $7.2M | $6.8M | |
| Other current liabilities | $22.3M | $20.4M | |
| Total current liabilities | $160.7M | $144.1M | |
| Operating leases, net of current portion | $30.0M | $23.3M | |
| Other liabilities | $4.0M | $3.4M | |
| Total liabilities | $194.7M | $170.8M | |
| Members' equity | $0 | $0 | |
| Additional paid-in capital | $139.4M | $125.5M | |
| Retained earnings | $66.3M | $17.1M | |
| Non-controlling interests | $12.2M | $7.3M | |
| Total equity | $217.9M | $150.0M | $59.9M |
| Total liabilities and equity | $412.7M | $320.8M |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $65.6M | $4.7M | |
| Accounts receivable, net | $101.6M | $97.2M | |
| Inventories | $43.4M | $40.5M | |
| Other current assets | $11.0M | $9.6M | |
| Total current assets | $221.6M | $152.0M | |
| Property and equipment, net | $55.5M | $49.9M | |
| Intangible assets, net | $18.5M | $14.9M | |
| Goodwill | $79.7M | $69.3M | |
| Operating lease right-of-use assets | $34.6M | $29.1M | |
| Deferred tax assets | $2.2M | $5.3M | |
| Other assets | $436.0K | $383.0K | |
| Total assets | $412.7M | $320.8M | |
| Accounts payable | $116.2M | $102.4M | |
| Accrued compensation | $15.0M | $14.4M | |
| Operating leases, current portion | $7.2M | $6.8M | |
| Other current liabilities | $22.3M | $20.4M | |
| Total current liabilities | $160.7M | $144.1M | |
| Operating leases, net of current portion | $30.0M | $23.3M | |
| Other liabilities | $4.0M | $3.4M | |
| Total liabilities | $194.7M | $170.8M | |
| Members' equity | $0 | $0 | |
| Additional paid-in capital | $139.4M | $125.5M | |
| Retained earnings | $66.3M | $17.1M | |
| Non-controlling interests | $12.2M | $7.3M | |
| Total equity | $217.9M | $150.0M | $59.9M |
| Total liabilities and equity | $412.7M | $320.8M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) | $49.0M | -$71.0M |
| Depreciation and amortization | $22.3M | $19.8M |
| Share-based compensation expense | $13.8M | $131.5M |
| Provision for losses on accounts receivable | $4.6M | $6.4M |
| Change in deferred tax asset | $3.1M | $0 |
| Other | $1.1M | $767.0K |
| Accounts receivable | -$8.6M | -$25.5M |
| Inventories | -$877.0K | -$1.2M |
| Other current assets | -$2.5M | -$2.0M |
| Accounts payable | $16.4M | $13.2M |
| Accrued compensation | $618.0K | -$3.0M |
| Other operating liabilities | $1.3M | -$11.1M |
| Net cash provided by operating activities | $100.3M | $58.0M |
| Purchases of property and equipment | -$19.5M | -$16.4M |
| Payment for acquisitions | -$13.4M | -$14.7M |
| Other | $736.0K | $671.0K |
| Net cash used in investing activities | -$32.2M | -$30.4M |
| Proceeds from equity offering, net of underwriter fees | $29.0M | $119.8M |
| Payments of equity offering costs | -$1.6M | -$4.2M |
| Borrowings from notes payable | $0 | $15.0M |
| Repayment of notes payable | -$497.0K | -$38.0M |
| Borrowings from line of credit | $0 | $189.3M |
| Repayments of line of credit | $0 | -$198.3M |
| Principal payments on finance lease obligations | -$4.5M | -$4.5M |
| Payments related to acquisitions | -$2.5M | $0 |
| Contributions from non-controlling interests | $2.0M | $2.8M |
| Distributions to non-controlling interests | -$458.0K | -$14.5M |
| Member distributions | $0 | -$35.8M |
| Other | $500.0K | -$160.0K |
| Net cash used in financing activities | -$7.1M | -$23.6M |
| Net change in cash and cash equivalents | $61.0M | $3.9M |
| Cash paid during the year for interest | $650.0K | $3.1M |
| Cash paid during the year for income taxes | $21.5M | $0 |
| Purchases of property and equipment through finance leases | $4.9M | $3.5M |
| Accrued and capitalized offering costs recorded to additional paid-in capital | $0 | $8.9M |
| Non-cash equity contributions from non-controlling members | $3.6M | $5.6M |
No quarter-by-quarter statement was filed.
Compare Guardian Pharmacy Services, Inc. with another company
Corporate structure
Guardian Pharmacy Services, Inc. sits at the top of its group. 55 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Guardian Pharmacy Services, Inc.
- Bindley Capital Partners I, LLC Filed SCHEDULE 13D/A on Guardian Pharmacy Services, Inc., latest Sep 28, 2026 (5 filings since Feb 3, 2025)
- FMR LLC Filed SCHEDULE 13G on Guardian Pharmacy Services, Inc., latest May 6, 2026
- BROWN ADVISORY INC Filed SCHEDULE 13G/A on Guardian Pharmacy Services, Inc., latest Feb 13, 2026 (4 filings since Dec 6, 2024)
- Wellington Management Company Filed SCHEDULE 13G/A on Guardian Pharmacy Services, Inc., latest Feb 10, 2026 (6 filings since Nov 8, 2024)
- BlackRock Filed SCHEDULE 13G/A on Guardian Pharmacy Services, Inc., latest Jan 21, 2026 (4 filings since Feb 4, 2025)
- J. Goldman & Co LP Filed SCHEDULE 13G/A on Guardian Pharmacy Services, Inc., latest Nov 14, 2025 (2 filings since Nov 14, 2024)
- Clearbridge Investments, LLC Filed SCHEDULE 13G/A on Guardian Pharmacy Services, Inc., latest Aug 5, 2025 (3 filings since Oct 31, 2024)
- Franklin Templeton Investments Filed SCHEDULE 13G/A on Guardian Pharmacy Services, Inc., latest Aug 5, 2025 (3 filings since Oct 31, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Guardian Pharmacy Services, Inc., latest Jul 29, 2025 (2 filings since Jan 30, 2025)
- Nuveen Asset Management, LLC Filed SCHEDULE 13G/A on Guardian Pharmacy Services, Inc., latest Jun 6, 2025 (2 filings since Nov 14, 2024)
- TEACHERS ADVISORS, LLC Filed SCHEDULE 13G/A on Guardian Pharmacy Services, Inc., latest Jun 6, 2025
- TIAA CREF INVESTMENT MANAGEMENT LLC Filed SCHEDULE 13G/A on Guardian Pharmacy Services, Inc., latest Jun 6, 2025 (2 filings since Nov 14, 2024)
- Guardian Pharmacy Services, Inc. Atlanta, Georgia
- 1. Guardian Pharmacy of Arizona, LLC Subsidiary · Indiana, United States
- 10. Guardian Pharmacy of Eastern NC, LLC Subsidiary · Georgia, United States
- 11. Guardian Pharmacy of Grand Island, LLC Subsidiary · Georgia, United States
- 12. Guardian Pharmacy of Grand Rapids, LLC Subsidiary · Georgia, United States
- 13. Guardian Pharmacy of Idaho Falls, LLC Subsidiary · Georgia, United States
- 14. Guardian Pharmacy of Indianapolis LTC, LLC Subsidiary · Georgia, United States
- 15. Guardian Pharmacy of Indianapolis Nuclear, LLC Subsidiary · Georgia, United States
- 16. Guardian Pharmacy of Iowa, LLC Subsidiary · Georgia, United States
- 17. Guardian Pharmacy of Jacksonville, LLC Subsidiary · Georgia, United States
- 18. Guardian Pharmacy of Kansas City, LLC Subsidiary · Georgia, United States
- 19. Guardian Pharmacy of Kentucky, LLC Subsidiary · Georgia, United States
- 2. Guardian Pharmacy of Atlanta, LLC Subsidiary · Georgia, United States
- 20. Guardian Pharmacy of Knoxville, LLC Subsidiary · Georgia, United States
- 21. Guardian Pharmacy of Madison, LLC Subsidiary · Georgia, United States
- 22. Guardian Pharmacy of Minneapolis, LLC Subsidiary · Georgia, United States
- 23. Guardian Pharmacy of Maine, LLC Subsidiary · Georgia, United States
- 24. Guardian Pharmacy of Minnesota, LLC Subsidiary · Georgia, United States
- 25. Guardian Pharmacy of Missouri, LLC Subsidiary · Georgia, United States
- 26. Guardian Pharmacy of Montana, LLC Subsidiary · Georgia, United States
- 27. Guardian Pharmacy of New Jersey, LLC Subsidiary · Georgia, United States
- 28. Guardian Pharmacy of Northern Virginia, LLC Subsidiary · Georgia, United States
- 29. Guardian Pharmacy of NW Florida, LLC Subsidiary · Georgia, United States
- 3. Guardian Pharmacy of Birmingham, LLC Subsidiary · Georgia, United States
- 30. Guardian Pharmacy of Oklahoma, LLC Subsidiary · Georgia, United States
- 31. Guardian Pharmacy of Oklahoma City, LLC Subsidiary · Georgia, United States
- and 29 more
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Guardian Pharmacy Services, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $143.4M2 Dec 31, 2025 | $127.9M2 Dec 31, 2024 | +12.1% |
| Accumulated depreciation | $87.8M2 Dec 31, 2025 | $78.0M2 Dec 31, 2024 | +12.7% |
| Property and equipment, net | $55.5M2 Dec 31, 2025 | $49.9M2 Dec 31, 2024 | +11.3% |
| Finance-lease assets | $7.2M2 Dec 31, 2025 | $6.9M2 Dec 31, 2024 | +5.1% |
| Operating-lease assets (leased space) | $34.6M2 Dec 31, 2025 | $29.1M2 Dec 31, 2024 | +19.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $65.6M2 Dec 31, 2025 | $4.7M2 Dec 31, 2024 | +1308.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $79.7M2 Dec 31, 2025 | $69.3M2 Dec 31, 2024 | +15.1% |
| Intangible assets, net (excluding goodwill) | $18.5M2 Dec 31, 2025 | $14.9M2 Dec 31, 2024 | +23.9% |
| Finite-lived intangibles, gross | $62.9M2 Dec 31, 2025 | $55.7M2 Dec 31, 2024 | +13.0% |
| Accumulated amortization | -$44.4M2 Dec 31, 2025 | -$40.8M2 Dec 31, 2024 | −9.0% |
| Finite-lived intangibles, net | $18.5M2 Dec 31, 2025 | $14.9M2 Dec 31, 2024 | +23.9% |
Inventory
Properties, in its own words
Our corporate headquarters occupy approximately 25,000 square feet in Atlanta, Georgia, under a lease that expires on October 31, 2030. We use this space for administration, sales, marketing, data analytics, and customer support. We have 65 additional leases in place for our local pharmacy operations and warehousing pharmaceuticals, totaling approximately 780,000 square feet.
Item 2 of the 10-K filed Mar 11, 2026.5
Leadership
Who has led Guardian Pharmacy Services, Inc., and when. Pick a name to see everywhere that person has worked.
Board members and other officers (17)
- OfficerChris Crisafulli Apr 13, 2026 to now10
- OfficerDavid Norman Martin Apr 13, 2026 to now11
- OfficerDouglas Towns Apr 13, 2026 to now12
- OfficerJeffrey Tuch Apr 13, 2026 to now13
- Senior Vice President, SalesRichard Eakins Apr 13, 2026 to now14
- OfficerRobert Weir Apr 13, 2026 to now15
- Senior Vice President, FinanceWilliam Franklin Mudd Apr 13, 2026 to now16
- OfficerDavid K. Morris Sep 25, 2024 to now17
- OfficerFred Burke Sep 25, 2024 to now18
- OfficerKendall Forbes Sep 25, 2024 to now19
- Board memberDavid K. Morris Sep 25, 2024 to now17
- Board memberFred Burke Sep 25, 2024 to now18
- Board memberMary Sue Patchett Sep 25, 2024 to now20
- Board memberRandall J. Lewis Sep 25, 2024 to now21
- Board memberSteven D. Cosler Sep 25, 2024 to now22
- Board memberThomas J. Salentine Jr. Sep 25, 2024 to now23
- Board memberWilliam E. Bindley Sep 25, 2024 to now24
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- 1. Guardian Pharmacy of Arizona, LLC Indiana4
- 10. Guardian Pharmacy of Eastern NC, LLC Georgia4
- 11. Guardian Pharmacy of Grand Island, LLC Georgia4
- 12. Guardian Pharmacy of Grand Rapids, LLC Georgia4
- 13. Guardian Pharmacy of Idaho Falls, LLC Georgia4
- 14. Guardian Pharmacy of Indianapolis LTC, LLC Georgia4
- 15. Guardian Pharmacy of Indianapolis Nuclear, LLC Georgia4
- 16. Guardian Pharmacy of Iowa, LLC Georgia4
- 17. Guardian Pharmacy of Jacksonville, LLC Georgia4
- 18. Guardian Pharmacy of Kansas City, LLC Georgia4
- 19. Guardian Pharmacy of Kentucky, LLC Georgia4
- 2. Guardian Pharmacy of Atlanta, LLC Georgia4
- 20. Guardian Pharmacy of Knoxville, LLC Georgia4
- 21. Guardian Pharmacy of Madison, LLC Georgia4
- 22. Guardian Pharmacy of Minneapolis, LLC Georgia4
- 23. Guardian Pharmacy of Maine, LLC Georgia4
- 24. Guardian Pharmacy of Minnesota, LLC Georgia4
- 25. Guardian Pharmacy of Missouri, LLC Georgia4
- 26. Guardian Pharmacy of Montana, LLC Georgia4
- 27. Guardian Pharmacy of New Jersey, LLC Georgia4
- 28. Guardian Pharmacy of Northern Virginia, LLC Georgia4
- 29. Guardian Pharmacy of NW Florida, LLC Georgia4
- 3. Guardian Pharmacy of Birmingham, LLC Georgia4
- 30. Guardian Pharmacy of Oklahoma, LLC Georgia4
All 54 listed subsidiaries
- 31. Guardian Pharmacy of Oklahoma City, LLC Georgia4
- 32. Guardian Pharmacy of Omaha, LLC Georgia4
- 33. Guardian Pharmacy of Oregon, LLC Georgia4
- 34. Guardian Pharmacy of Orlando, LLC Georgia4
- 35. Guardian Pharmacy of Piedmont Carolinas, LLC Georgia4
- 36. Guardian Pharmacy of South Carolina One, LLC Georgia4
- 37. Guardian Pharmacy of Southeast Florida, LLC Georgia4
- 38. Guardian Pharmacy of Southeast Georgia, LLC Georgia4
- 39. Guardian Pharmacy of Southern California, LLC Georgia4
- 4. Guardian Pharmacy of Boise, LLC Georgia4
- 40. Guardian Pharmacy of Southwest Florida, LLC Georgia4
- 41. Guardian Pharmacy of St. Louis, LLC Georgia4
- 42. Guardian Pharmacy of Tampa, LLC Georgia4
- 43. Guardian Pharmacy of Tennessee One, LLC Georgia4
- 44. Guardian Pharmacy of Tennessee Two, LLC Georgia4
- 45. Guardian Pharmacy of Tennessee Three, LLC Georgia4
- 46. Guardian Pharmacy of Texas, LLC Georgia4
- 47. Guardian Pharmacy of Tucson, LLC Georgia4
- 48. Guardian Pharmacy of Tulsa, LLC Georgia4
- 49. Guardian Pharmacy of Utah, LLC Georgia4
- 5. Guardian Pharmacy of Cincinnati, LLC Georgia4
- 50. Guardian Pharmacy of Virginia, LLC Georgia4
- 51. Guardian Pharmacy of Washington, LLC Georgia4
- 52. Guardian Pharmacy of Wichita, LLC Georgia4
- 53. Guardian Pharmacy Services Management, LLC Georgia4
- 54. Guardian Pharmacy, LLC Indiana4
- 6. Guardian Pharmacy of Colorado, LLC Georgia4
- 7. Guardian Pharmacy of Columbus, LLC Georgia4
- 8. Guardian Pharmacy of Daytona, LLC Georgia4
- 9. Guardian Pharmacy of Denver, LLC Georgia4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Guardian Pharmacy, LLCFeb 13, 2020 to Jul 23, 20213
Timeline
- Sep 10, 20268-K Other events25
- Aug 6, 20268-K Results of operations26
- Jun 22, 20268-K Executive or director change; Regulation FD disclosure27
- May 28, 20268-K Entered a material agreement; New debt or obligation28
- May 7, 20268-K Shareholder vote29
- May 6, 20268-K Results of operations30
- Mar 23, 20268-K Entered a material agreement; Other events31
- Mar 11, 20268-K Results of operations32
- Jan 13, 20268-K Results of operations; Regulation FD disclosure33
- Nov 10, 20258-K Results of operations34
- Oct 14, 20258-K Other events35
- Sep 18, 20258-K Regulation FD disclosure36
Calendar
Coming up
- Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.19 a share, on Nov 10, 2025.37
When it reported results
- Aug 6, 2026Reported quarterly or annual results26
- May 6, 2026Reported quarterly or annual results30
- Mar 11, 2026Reported quarterly or annual results32
- Jan 13, 2026Reported quarterly or annual results33
- Nov 10, 2025Reported quarterly or annual results34
- Aug 11, 2025Reported quarterly or annual results38
- May 12, 2025Reported quarterly or annual results39
- Mar 26, 2025Reported quarterly or annual results40
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
215 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 24 major events, 101 insider forms, 41 large holders, 41 other. The latest 20:
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 2026SCHEDULE 13D/A EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 10, 20268-K EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
The 215 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
33 open-market trades by officers, directors and large owners since October 2021: 6 buys and 27 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 20, 2026 | Morris David KSee Remarks | Sale | 187,855 | $29.68 | $5.6M | Form 4 |
| Mar 20, 2026 | Pharmacy Investors, LLC | Sale | 827,636 | $29.68 | $24.6M | Form 4 |
| Mar 20, 2026 | Burke FredSee Remarks | Sale | 671,432 | $29.68 | $19.9M | Form 4 |
| Mar 20, 2026 | Salentine Thomas J JrDirector | Sale | 3,570,677 | $29.68 | $106.0M | Form 4 |
| Mar 20, 2026 | Bindley Capital Partners I, LLC10% owner | Sale | 3,570,677 | $29.68 | $106.0M | Form 4 |
| Mar 20, 2026 | Ackerman JohnDirector | Sale | 1,103,364 | $29.68 | $32.7M | Form 4 |
| Mar 20, 2026 | BINDLEY WILLIAM EDirector | Sale | 3,570,677 | $29.68 | $106.0M | Form 4 |
| Mar 20, 2026 | Forbes Kendall | Sale | 346,672 | $29.68 | $10.3M | Form 4 |
| Mar 20, 2026 | Cardinal Equity Fund, L.P. | Sale | 275,728 | $29.68 | $8.2M | Form 4 |
| Dec 3, 2025 | COSLER STEVEN DDirector | Buy | 3,370 | $29.61 | $99.8K | Form 4 |
| May 28, 2025 | Cardinal Equity Fund, L.P. | Sale | 50,305 | $20.16 | $1.0M | Form 4 |
| May 28, 2025 | Pharmacy Investors, LLC | Sale | 150,998 | $20.16 | $3.0M | Form 4 |
| May 28, 2025 | BINDLEY WILLIAM EDirector | Sale | 651,454 | $20.16 | $13.1M | Form 4 |
| May 28, 2025 | Salentine Thomas J JrDirector | Sale | 651,454 | $20.16 | $13.1M | Form 4 |
| May 28, 2025 | Ackerman JohnDirector | Sale | 201,303 | $20.16 | $4.1M | Form 4 |
| May 28, 2025 | Morris David KSee Remarks | Sale | 68,547 | $20.16 | $1.4M | Form 4 |
| May 28, 2025 | Burke FredSee Remarks | Sale | 138,705 | $20.16 | $2.8M | Form 4 |
| May 28, 2025 | Forbes Kendall | Sale | 64,991 | $20.16 | $1.3M | Form 4 |
| May 28, 2025 | Bindley Capital Partners I, LLC10% owner | Sale | 651,454 | $20.16 | $13.1M | Form 4 |
| May 27, 2025 | Cardinal Equity Fund, L.P. | Sale | 270,958 | $20.16 | $5.5M | Form 4 |
All 33 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Bindley Capital Partners I, LLCSCHEDULE 13D/A, 5 filings Feb 3, 2025 to Sep 28, 202641
- FMR LLCSCHEDULE 13G, 1 filing May 6, 202642
- BROWN ADVISORY INCSCHEDULE 13G/A, 4 filings Dec 6, 2024 to Feb 13, 202643
- Wellington Management CompanySCHEDULE 13G/A, 6 filings Nov 8, 2024 to Feb 10, 202644
- BlackRockSCHEDULE 13G/A, 4 filings Feb 4, 2025 to Jan 21, 202645
- J. Goldman & Co LPSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Nov 14, 202546
- Clearbridge Investments, LLCSCHEDULE 13G/A, 3 filings Oct 31, 2024 to Aug 5, 202547
- Franklin Templeton InvestmentsSCHEDULE 13G/A, 3 filings Oct 31, 2024 to Aug 5, 202548
- VANGUARD GROUP INCSCHEDULE 13G/A, 2 filings Jan 30, 2025 to Jul 29, 202549
- Nuveen Asset Management, LLCSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Jun 6, 202550
- TEACHERS ADVISORS, LLCSCHEDULE 13G/A, 1 filing Jun 6, 202551
- TIAA CREF INVESTMENT MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Jun 6, 202552
- Alyeska Investment Group, L.P.SCHEDULE 13G/A, 2 filings Nov 14, 2024 to Feb 14, 202553
- Woodline Partners LPSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Feb 14, 202554
- Ophir Asset Management Pty LtdSCHEDULE 13G/A, 2 filings Oct 8, 2024 to Jan 2, 202555
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Executive VicePresident and Chief Financial Officer | $412.0K | $996.7K56 | |
| 2025 | Executive Vice PresidentSales & Operations | $412.0K | $994.7K56 | |
| 2025 | President and Chief Executive Officer | $463.5K | $845.8K56 | |
| 2024 | President and Chief Executive Officer | $450.0K | $766.1K56 | |
| 2024 | Executive VicePresident and Chief Financial Officer | $400.0K | $684.3K56 | |
| 2024 | Executive Vice PresidentSales & Operations | $400.0K | $681.0K56 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 3,241,612 | $135.7M | 0.0% | +882,255 |
| Wellington Management Group Llp | 1,729,032 | $72.4M | 0.0% | −36,087 |
| BlackRock, Inc. | 1,575,989 | $66.0M | 0.0% | −180,385 |
| Vanguard Capital Management LLC | 1,379,750 | $57.8M | 0.0% | +154,207 |
| Woodline Partners LP | 1,306,340 | $54.7M | 0.2% | +22 |
| Valiant Capital Management, L.P. | 1,186,658 | $49.7M | 3.1% | No change |
| Boston Partners | 983,868 | $40.8M | 0.0% | −33,815 |
| Franklin Resources Inc | 966,206 | $40.5M | 0.0% | +13,254 |
| TimesSquare Capital Management, LLC | 951,637 | $39.8M | 0.6% | −125,837 |
| Loomis Sayles & Co L P | 869,836 | $36.4M | 0.0% | −61,853 |
| Boone Capital Management LLC | 711,939 | $29.8M | 7.0% | +80,746 |
| Geode Capital Management, LLC | 646,695 | $27.1M | 0.0% | +87,660 |
| Jennison Associates LLC | 626,664 | $26.2M | 0.0% | −196,120 |
| State Street Corp | 590,114 | $24.7M | 0.0% | +81,096 |
| Brown Advisory Inc | 524,013 | $21.9M | 0.0% | −735,161 |
| Dimensional Fund Advisors LP | 516,094 | $21.6M | 0.0% | +307,500 |
| Driehaus Capital Management LLC | 510,161 | $21.4M | 0.1% | −78,960 |
| First Trust Advisors LP | 461,307 | $19.3M | 0.0% | +367,630 |
| Aristotle Capital Boston, LLC | 422,427 | $17.7M | 1.2% | −73,429 |
| Silvercrest Asset Management Group LLC | 345,229 | $14.5M | 0.1% | −29,717 |
| Braun Stacey Associates Inc | 339,947 | $14.2M | 0.4% | New |
| Morgan Stanley | 312,004 | $13.1M | 0.0% | +195,036 |
| Raymond James Financial Inc | 307,879 | $12.9M | 0.0% | +46,860 |
| Royal Bank Of Canada | 301,400 | $12.6M | 0.0% | +299,899 |
| Alyeska Investment Group, L.P. | 275,000 | $11.5M | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Guardian Pharmacy Services, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARGuardian Pharmacy Services, Inc.1
- CIK0001802255
- Employer ID (EIN)87-36271395
- Filer statusAccelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)5912 Retail-Drug Stores and Proprietary Stores1
- SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
- Business address300 Galleria Parkway Se, Suite 800, Atlanta, GA 303391
- Phone(404) 810-00891
- Shares outstanding36,253,744 Common Class A shares; 27,066,890 Common Class B shares as of Mar 2, 20265
- Public float$411.6M as of Jun 30, 20255
- AuditorErnst & Young LLP, Atlanta, Georgia PCAOB ID 42; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceFeb 13, 20201
- Filings223 in all: 4 (82), 8-K (24), SCHEDULE 13G/A (20), 3 (19), SCHEDULE 13G (9), SC 13G (7), UPLOAD (7), 10-Q (6)1
All 31 form types
DRS/A (6), CORRESP (5), DRSLTR (5), SCHEDULE 13D/A (4), 10-K (2), 424B4 (2), 424B5 (2), DEF 14A (2), DEFA14A (2), DRS (2), EFFECT (2), S-1 (2), S-1/A (2), S-8 (2), 424A (1), 424B3 (1), 8-A12B (1), CERT (1), S-1MEF (1), S-3 (1), S-3ASR (1), S-3MEF (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (10-K) Mar 11, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Mar 26, 2026
Latest 8-K (8-K) Sep 10, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Class A Common Stock, par value $0.001 per share | GRDN | NYSE |
From the cover page of the 10-K filed Mar 11, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Guardian Pharmacy Services, Inc. names in Item 1A of its 10-K filed Mar 11, 2026: 42 risks under these headings, as written.5
- Risks Related to Our Business
- Intense competition may erode our profit margins.
- Our prescription volumes may decline, and our operating results may be negatively impacted, if products are withdrawn from the market or if increased safety risk profiles of specific drugs result in utilization decreases.
- If we lose relationships with one or more pharmaceutical wholesalers or key manufacturers, or if such wholesalers or manufacturers refuse to extend our relationships on the same or similar terms, our business and financial results could be materially and adversely affected.
- Our operating results may suffer if we fail to maintain certain relationships and contracts with LTCFs we serve.
- The COVID-19 pandemic negatively impacted LTCFs and harmed our business. Another similar public health crisis, outbreak of infectious disease or national emergency could also have a negative impact on our business.
- The impact of ongoing healthcare reform efforts on our business cannot accurately be predicted, and continuing government and private efforts to lower pharmaceutical costs, including by capping the prices for certain drugs and by limiting reimbursements, may adversely impact our profitability, results of operations and financial condition.
- If we fail to comply with Medicare and Medicaid regulations, we may be subjected to reduction in reimbursement, overpayment demands, or loss of eligibility to participate in these programs.
- Further modifications to the Medicare Part D program may reduce revenue and impose additional costs to the industry.
- Further consolidation of managed care organizations and other health plan payors, and changes in the terms of our agreements with these parties, may adversely affect our profits.
- We are highly dependent on our senior management team, our local pharmacy management teams and our pharmacy professionals and the loss of such persons could cause our business to suffer and materially adversely affect our operating results.
- Continued inflation and increases in labor costs may reduce our profitability.
The other 31 risks
- Government efforts to combat inflation, along with other interest rate pressures arising from an inflationary economic environment, could lead to us to incur even higher interest rates and financing costs and may reduce our profitability.
- Labor shortages could harm our ability to implement our growth strategy.
- If we or the LTCFs we serve fail to comply with state licensure requirements, we could be prevented from providing pharmacy services or be required to make significant changes to our operations.
- Complex and rapidly evolving laws and regulations could cause us to make significant changes to our operations or incur substantial costs or penalties.
- If we fail to comply with fraud and abuse laws, false claims provisions or other applicable laws, we may need to curtail operations, and could be subject to significant penalties.
- Federal and state privacy and security regulations may increase our cost of operations and expose us to civil and criminal sanctions, damages, and penalties.
- The increasing enforcement environment in the U.S. healthcare industry may negatively impact our business.
- Adverse results in material litigation matters or governmental inquiries could have a material adverse effect upon our business.
- Interruptions to our information systems may materially and adversely affect our operating results.
- Our business success and results of operations depend in part on our ability to use technology effectively in our dispensing of prescriptions, and if we cannot keep pace with technological developments or continue to innovate and provide new programs, products and services, the use of our services and our revenue could decline.
- Cybersecurity attacks or other data security incidents could disrupt our operations and expose us to regulatory fines or penalties, liability or reputational harm.
- We could be adversely affected by product liability, product recall, personal injury or other health and safety issues, and our insurance coverage may not be adequate to protect us against all potential risks and claims against us.
- Supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense could adversely impact our business.
- Acquisitions and strategic alliances that we have made or may make in the future could require significant resources, may be unsuccessful and could expose us to unforeseen liabilities.
- Some of the pharmaceuticals we dispense are warehoused with a single logistics provider for warehouse and distribution services to our pharmacies, and our business could be harmed if our logistics provider performs poorly, fails to comply with its licensing requirements or is unavailable and we are unable to replace it.
- We may be exposed to potential liability and reputational harm if LTCF caregivers fail to properly administer the pharmaceuticals we dispense.
- The misuse or off-label use of the pharmaceuticals we dispense may harm our image in the marketplace, result in injuries that lead to product liability suits or result in costly investigations and sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.
- We may be exposed to potential liability and reputational harm if we make errors in the course of providing medication reconciliation, duplicate therapy resolution, clinical issue resolution and related services.
- Our future success depends upon our ability to maintain and manage our growth. If we are unable to manage our growth effectively, we may incur unexpected expenses and be unable to meet the demands of our customers and other constituents.
- Our revenues and volume trends may be adversely affected by certain factors relevant to the markets in which we have pharmacies, including weather conditions and other natural disasters, some of which may not be covered by insurance.
- Risks Related to Ownership of Our Class A Common Stock
- The Guardian Founders are able to exercise significant control over us, including through the election of all of our directors.
- We are a “controlled company” within the meaning of the corporate governance standards of NYSE. As a result, we qualify for exemptions from certain corporate governance standards and you do not have the same protections afforded to stockholders of companies that are subject to such requirements.
- Our future issuance of Class A common stock, Class B common stock, preferred stock or convertible debt securities could dilute our common stockholders and adversely affect the market value of our Class A common stock.
- The market price of shares of our Class A common stock has experienced, and may in the future experience, substantial volatility.
- The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain qualified board members.
- Future sales, or the perception of future sales of Class A common stock, by us or our existing stockholders in the public market could cause the market price for our common stock to decline.
- If we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our Class A common stock may decline.
- We do not intend to pay any cash dividends on our common stock in the foreseeable future.
- We are a holding company with no operations of its own and, accordingly, we depend on our subsidiaries for cash to fund our operations and expenses, including future dividend payments, if any.
- Our certificate of incorporation and bylaws and provisions of Delaware law may discourage or prevent certain strategic transactions, including a takeover of our company, even if such a transaction would be beneficial to our stockholders.
- Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders and the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Legal proceedings
From time to time, we and our pharmacies are involved and will continue to be involved in various claims relating to, and arising out of, our business and our operations. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARChris Crisafulli, Officer
- 11SEC EDGARDavid Norman Martin, Officer
- 12SEC EDGARDouglas Towns, Officer
- 13SEC EDGARJeffrey Tuch, Officer
- 14
- 15SEC EDGARRobert Weir, Officer
- 16
- 17SEC EDGARDavid K. Morris, Officer
- 18SEC EDGARFred Burke, Officer
- 19SEC EDGARKendall Forbes, Officer
- 20SEC EDGARMary Sue Patchett, Board member
- 21SEC EDGARRandall J. Lewis, Board member
- 22SEC EDGARSteven D. Cosler, Board member
- 23
- 24SEC EDGARWilliam E. Bindley, Board member
- 25SEC EDGAROther events
- 26SEC EDGARResults of operations
- 27
- 28
- 29SEC EDGARShareholder vote
- 30SEC EDGARResults of operations
- 31
- 32SEC EDGARResults of operations
- 33
- 34SEC EDGARResults of operations
- 35SEC EDGAROther events
- 36SEC EDGARRegulation FD disclosure
- 37NasdaqNasdaq calendar
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56